The deficiency of the homologous recombination pathway also represents an “Achilles heel” of the tumor, with the development of molecules that take advantage of this inactivation (PARP inhibitors and chemotherapy with platinum salts in particular) [14,15,16]. The gene discussed is PARP1; the disease is neoplasm.